RCT
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Linda Stein Gold, Hilary Baldwin, Leon H Kircik, Jonathan S Weiss, David M Pariser, Valerie Callender + 8 more
RCTAmerican journal of clinical dermatology2022n=741
Research Facts
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Linda Stein Gold, Hilary Baldwin, Leon H Kircik, Jonathan S Weiss, David M Pariser, Valerie Callender + 8 more
RCT · Strong · 2022
Findings

In a 12-week study of 741 people with moderate-to-severe acne, the triple-combo gel (clindamycin + benzoyl peroxide + adapalene) cleared skin in 52.5% of users versus 8.1% with placebo. It reduced inflammatory spots by about 30 and non-inflammatory ones by about 35, outperforming two-ingredient versions. Side effects were mostly mild to moderate.

Design
RCT
Sample
n=741
Evidence
Strong
Journal
American journal of clinical dermatology
Methodology

Researchers randomly assigned acne patients aged 9+ to either the triple-combo gel, placebo, or three different two-ingredient combinations. They measured success by looking at skin improvement and counting lesions over 12 weeks.

Funded By

Funding not disclosed in abstract